0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Kidney injury molecule-1 inhibits metastasis of renal cell carcinoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Metastasis is present in approximately 30% of patients diagnosed with renal cell carcinoma (RCC) and is associated with a 5-year survival rate of < 15%. Kidney injury molecule 1 (KIM-1), encoded by the HAVCR1 gene, is a proximal tubule cell-surface glycoprotein and a biomarker for early detection of RCC, but its pathophysiological significance in RCC remains unclear. We generated human and murine RCC cell lines either expressing or lacking KIM-1, respectively, and compared their growth and metastatic properties using validated methods. Surprisingly, KIM-1 expression had no effect on cell proliferation or subcutaneous tumour growth in immune deficient (Rag1 −/−) Balb/c mice, but inhibited cell invasion and formation of lung metastasis in the same model. Further, we show that the inhibitory effect of KIM-1 on metastases was observed in both immune deficient and immune competent mice. Transcriptomic profiling identified the mRNA for the pro-metastatic GTPase, Rab27b, to be downregulated significantly in KIM-1 expressing human and murine RCC cells. Finally, analysis of The Cancer Genome Atlas (TCGA) data revealed that elevated HAVCR1 mRNA expression in the two most common types of RCC, clear cell and papillary RCC, tumours correlated with significantly improved overall patient survival. Our findings reveal a novel role for KIM-1 in inhibiting metastasis of RCC and suggests that tumour-associated KIM-1 expression may be a favourable prognostic factor.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

          Background RNA-Seq is revolutionizing the way transcript abundances are measured. A key challenge in transcript quantification from RNA-Seq data is the handling of reads that map to multiple genes or isoforms. This issue is particularly important for quantification with de novo transcriptome assemblies in the absence of sequenced genomes, as it is difficult to determine which transcripts are isoforms of the same gene. A second significant issue is the design of RNA-Seq experiments, in terms of the number of reads, read length, and whether reads come from one or both ends of cDNA fragments. Results We present RSEM, an user-friendly software package for quantifying gene and isoform abundances from single-end or paired-end RNA-Seq data. RSEM outputs abundance estimates, 95% credibility intervals, and visualization files and can also simulate RNA-Seq data. In contrast to other existing tools, the software does not require a reference genome. Thus, in combination with a de novo transcriptome assembler, RSEM enables accurate transcript quantification for species without sequenced genomes. On simulated and real data sets, RSEM has superior or comparable performance to quantification methods that rely on a reference genome. Taking advantage of RSEM's ability to effectively use ambiguously-mapping reads, we show that accurate gene-level abundance estimates are best obtained with large numbers of short single-end reads. On the other hand, estimates of the relative frequencies of isoforms within single genes may be improved through the use of paired-end reads, depending on the number of possible splice forms for each gene. Conclusions RSEM is an accurate and user-friendly software tool for quantifying transcript abundances from RNA-Seq data. As it does not rely on the existence of a reference genome, it is particularly useful for quantification with de novo transcriptome assemblies. In addition, RSEM has enabled valuable guidance for cost-efficient design of quantification experiments with RNA-Seq, which is currently relatively expensive.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

            Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.

              Researchers have been studying metastasis for more than 100 years, and only recently have we gained insight into the mechanisms by which metastatic cells arise from primary tumours and the reasons that certain tumour types tend to metastasize to specific organs. Stephen Paget's 1889 proposal that metastasis depends on cross-talk between selected cancer cells (the 'seeds') and specific organ microenvironments (the 'soil') still holds forth today. It is now known that the potential of a tumour cell to metastasize depends on its interactions with the homeostatic factors that promote tumour-cell growth, survival, angiogenesis, invasion and metastasis. How has this field developed over the past century, and what major breakthroughs are most likely to lead to effective therapeutic approaches?
                Bookmark

                Author and article information

                Contributors
                Lakshman.Gunaratnam@lhsc.on.ca
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                4 June 2021
                4 June 2021
                2021
                : 11
                : 11840
                Affiliations
                [1 ]GRID grid.39381.30, ISNI 0000 0004 1936 8884, Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, , Western University, ; London, ON Canada
                [2 ]GRID grid.415847.b, ISNI 0000 0001 0556 2414, Matthew Mailing Centre for Translational Transplant Studies, , Lawson Health Research Institute, ; London, ON Canada
                [3 ]GRID grid.411081.d, ISNI 0000 0000 9471 1794, Centre de recherche du CHU de Québec-Université Laval, , CHU de Québec-Université Laval, ; Quebec City, QC Canada
                [4 ]GRID grid.413104.3, ISNI 0000 0000 9743 1587, Sunnybrook Health Sciences Centre, ; Toronto, ON Canada
                [5 ]GRID grid.39381.30, ISNI 0000 0004 1936 8884, Division of Nephrology, Department of Medicine, Schulich School of Medicine and Dentistry, , Western University, ; Room A10-208, 339 Windermere Road, London, ON N6A 5A5 Canada
                Author information
                http://orcid.org/0000-0002-8845-1126
                Article
                90919
                10.1038/s41598-021-90919-8
                8178330
                34088927
                173b0204-64e7-43ac-94f3-4d203367c7b5
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 20 December 2020
                : 19 May 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100013873, Government of Ontario;
                Funded by: FundRef http://dx.doi.org/10.13039/100008958, Lawson Health Research Institute;
                Funded by: FundRef http://dx.doi.org/10.13039/100008957, London Health Sciences Centre;
                Funded by: FundRef http://dx.doi.org/10.13039/501100008093, Schulich School of Medicine and Dentistry;
                Categories
                Article
                Custom metadata
                © The Author(s) 2021

                Uncategorized
                cancer genomics,metastasis,renal cell carcinoma
                Uncategorized
                cancer genomics, metastasis, renal cell carcinoma

                Comments

                Comment on this article